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Abstract. – OBJECTIVE: Nasal administration 
of Streptococcus salivarius 24SMB and Strepto-
coccus oralis 89a has been proposed to reduce 
the risk of new episodes of adenoiditis, tonsillitis 
and acute rhinosinusitis in children.
PATIENTS AND METHODS: We enrolled 202 
children with a recent diagnosis of recurrent upper 
respiratory tract infection. All the patients were 
treated twice daily for 7 days each month for 3 
consecutive months with a nasal spray whose 
active agents were two specific bacterial strains: 
Streptococcus salivarius 24SMB and Streptococ-
cus oralis 89a. Evaluation was performed at the end 
of treatment and at follow-up at 3, 6, and 12 months.
RESULTS: Patients who completed the entire 
90-day course of bacteriotherapy and the follow-up 
period showed a 64.3% reduction in their episodes 
of upper respiratory tract infections compared to 
the number of episodes recorded in the previous 
year. Treatment decreased the reported incidence 
of infection events by 52.4% in the first 3 months, 
31.2% at 6-month follow-up, and 20.8% after 12 
months. Enrolled patients tolerated the product 
well, and there were no dropouts.  
CONCLUSIONS: Prophylactic bacteriothera-
py by administration of Streptococcus salivari-
us 24SMB and Streptococcus oralis 89a in chil-
dren with a history of recurrent upper respirato-
ry tract infection could reduce the number of epi-
sodes of otolaryngologic infections. Bacteriother-
apy can be even more clinically important due to 
increasing difficulty in finding new effective an-
tibiotic compounds. New alternative therapeutic 
approaches must be found with, in comparison 
to antibiotics, greater specificity and safety with 
respect to patients’ native beneficial flora; lack of 
drug interactions; the ability to leverage comple-
mentary systemic modes of action; and drastical-
ly reduced risk of developing resistance within the 
patient population and the environment.
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Introduction
The capability of microbes to adapt to their 
environment is evident in the human body as in 
other living organisms. Commensal microorgan-
isms and their metabolites maintain the stability 
of their habitat and the health of their host as a 
symbiotic system. Even inflammation plays a role 
in the creation of a microenvironment in which 
certain microbes can or cannot grow and repro-
duce1,2. Consideration of such changes in the mi-
crobiome as cause or effect of the counteraction 
of the host defense is still debated, particularly in 
a number of chronic inflammatory conditions as-
sociated with disrupted epithelia. The occupation 
of upper respiratory tract (URT) niches by indig-
enous flora can induce resistance against other 
pathogens. As a result, an invading pathogen has 
the unenviable task of competing with established 
commensal flora for adhesion receptors and nutri-
ents on the mucosal surface – a competition that 
limits the chances of adhesion, replication, a dis-
semination of disease.
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Microbes can physiologically develop the ca-
pacity to inhibit competing microbes using an-
timicrobial compounds. A prime example is the 
production of hydrogen peroxide by Streptococ-
cus pneumoniae, which is bactericidal for Staph-
ylococcus aureus3. Moreover, some bacterial 
species produce peptides with antimicrobial effi-
cacy, generally referred to as bacteriocins4. This 
mechanism is clearly evident in the commensal 
streptococcal species Streptococcus salivarius, 
which inhibits pathogenic Streptococcus pyo-
genes growth by the production of bacteriocins. 
The large surface of the nasal cavity contains 
niches shaping the ecosystem’s habitat, and an-
tibiotic treatment as well as invading pathogens 
may break this balance5. Indigenous microbiotic 
species make a large contribution to resisting col-
onization by invading pathogens6. The presence 
of so-called keystone species is strongly related 
to the maintenance of biodiversity in ecological 
communities; their loss results in the extinction of 
many other (micro-) organisms, hence decreasing 
the community’s biodiversity7.
The diversity of the microbiota used by com-
mensal bacteria and pathogens is mainly due to 
the mechanisms of molecules of the innate im-
munity8-10, specifically the expression of differ-
ent Toll-like Receptors (TLRs) on the respiratory 
epithelial cells. In this case, an important role is 
played by inflammation. Bacteria that induce low-
grade asymptomatic inflammation may create 
conditions enabling easier penetration and inva-
sion by pathogenic bacteria. For example, coloni-
zation with proteobacteria such as non-typeable 
Haemophilus influenzae, which is accompanied 
by mucosal inflammation, is characterized by in-
creased epithelial thickness of the large airways, 
production of early pro-inflammatory cytokines, 
and damage of the epithelial barrier function11. 
In contrast, in Chronic Obstructive Pulmo-
nary Disease (COPD), commensal strains such as 
Prevotella, antagonize pathogens lipopolysaccha-
ride (LPS)-mediated TLR4-signalling with damp-
ening and downstream signaling, contributing to 
mucosal homeostasis and colonization resistance 
vs. pathogens12. 
Skewed inflammatory mediator expression 
can also be influenced by environmental factors 
such as cigarette smoke13. These factors can also 
influence the interplay between innate immunity 
and mucosal microbial communities. The delicate 
balance of these factors makes the healthy micro-
biome an important component of the epithelial 
barrier14.
Focusing now on the commensal microorgan-
isms of the upper airways, the α-hemolytic strep-
tococcus is mostly present in the nasopharynx 
and may interfere with survival and multiplica-
tion of pathogens that are most often associated 
with development of acute otitis media (AOM) 
and its consequences such as acquired hearing 
loss15,16. More recently, specific types of α-he-
molytic streptococcus have been isolated from 
the pharynx of healthy subjects: Streptococcus 
salivarius 24SMB and Streptococcus oralis 89a. 
These microbes are potential nasopharyngeal 
probiotics, with immunomodulatory and anti-in-
flammatory skills, production of plasmin-encod-
ed bacteriocins and a good safety profile 17-19. The 
first study with Streptococcus salivarius 24SMB, 
recently published by Marchisio et al 20, reported 
significant activity against AOM pathogens when 
Streptococcus salivarius is administrated intra-
nasal in otitis-prone children. 
The aim of this study is to evaluate the role of 
Streptococcus salivarius 24SMB and Streptococ-
cus oralis 89a in the treatment and prevention of 
recurrent URT infections in children.
Patients and methods
Two hundred and two patients presenting to our 
University Hospital from September 2016 to Febru-
ary 2017 were included in the study. The study was 
specifically approved by the Ethical Committee of 
our University Hospital. One-hundred forty-one 
subjects were males and 61 were females, with a 
median age of 7.5 years. The patients were included 
after the collection of anamnestic data and clinical 
evaluation that reported recurrent URT pathology 
treated with systemic antibiotic therapy by own 
family physician. The URT conditions analyzed in 
the present study were adenoiditis, tonsillitis, and 
acute rhinosinusitis. 
Patients with severe concomitant diseases or 
lacking consent from their parents/caregivers 
were excluded from the study. All patients were 
treated with a nasal spray made up of a suspen-
sion of two specific bacterial strains: Streptococ-
cus salivarius 24SMB and Streptococcus oralis 
89a. This topical treatment was administered via 
intranasal spray using a disposable device twice 
daily for 7 days per month for 3 consecutive 
months. Patients were previously treated with an 
antibiotic and started the new intervention after 
10 days of washout from antibiotic therapy. The 
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treatment was concomitant with saline nasal ir-
rigations in 40% of patients, with vasoconstric-
tor drops in 6% and with oral antihistamines in 
6%. A questionnaire about the subjective efficacy 
of the therapy was collected from adult patients 
and from children’s parents and/or caregivers and 
compared to clinical improvement of symptoms. 
Results obtained during therapy were compared 
with those of the previous year for each subject as 
reported by their parents.
Results
One year after the beginning of bacteriother-
apy, a 64.3% of reduction in the number of ob-
served events compared to the previous year was 
reported (Figure 1); similar results were observed 
for the number of recurrent episodes in specific 
URT pathologies. 
The frequency of recurrences was evaluated 
as the reduction of episodes during follow-up at 3, 
6, and 12 months. The highest percentage of URT 
events (57.3%) occurred in the first three months 
of treatment with a progressive decrease over the 
remaining period (24.9% at 6 months and 17.8% 
after 12 months). This overall trend was con-
firmed for each pathological condition: the recur-
rence percentage in patients affected by adenoid-
itis was 48.2% during the first 3 months, 29.5% at 
6 months and 22.3% at the final follow-up visit; 
in patients affected by adenotonsillitis the recur-
rence rate was 51.7% during the first 3 months, 
23.8% at 6 months and 24.5% at final follow-up; 
recurrence in patients affected by rhinosinusitis 
was 71.9% during the first 3 months, 21.3% at 6 
months and 6.8% at final follow-up (Figure 2).
These results were confirmed by the subjective 
self-administered questionnaires on the efficacy 
of the therapeutic protocol: 58.7% of the patients 
reported a positive change in their symptoms and 
recurrence rate; 36.1% reported doubtful changes 
and improvement; 8% of treated patients report-
ed a worsening of symptoms. Among symptoms 
collected from the questionnaires, a statistically 
significant improvement (p <0.05) was observed 
for nasal obstruction and ear fullness (Figure 3). 
Figure 1. Data collected 12 months 
after beginning treatment. A, Per-
centage of upper respiratory tract 
infections in enrolled patients com-
pared to data of the previous year 
from the same patients. B,  Number 
of upper respiratory tract infections 
in enrolled patients compared to data 
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Figure 2. Data collected during follow up. Data collected during follow up 3, 6, and 12 months after the beginning of treat-
ment for each pathological condition (adenoiditis, tonsillitis, rhinosinusitis).
Figure 3. Subjective report on the 
efficacy of the therapeutic protocol. 
Subjective report on the efficacy of 
the therapeutic protocol recorded 
12 months after the beginning of 
treatment using self-administered 
questionnaires. Most of the pa-
tients reported an improvement in 
symptoms; a small percentage re-
ported a worsened condition.
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Discussion
URT infections are the most common cause 
of consultation both for general practitioners and 
otolaryngologists worldwide, and they repre-
sent an important cause of reduced school days, 
work loss, and increased healthcare expenses. 
The significant burden of care in otolaryngo-
logic pathology is represented by the need for 
medical examination, prescription of antipyret-
ic medicaments, and often antibiotics. Beyond 
direct costs, URT infections involve high indi-
rect costs in terms of loss of educational access 
and progress for the child kept home to rest, and 
economic productivity of the parental caregiver. 
Such negative effects are multiplied in the case 
of recurrent infection 21.
Unfortunately, inflammation of the rhinophar-
ynx and oropharynx in children with adenotonsil-
lar hypertrophy is underestimated and poorly 
treated, leading to complications in the middle 
ear and paranasal sinuses. Middle ear complica-
tions follow impaired ventilation following tubal 
obstruction. Viral or allergic inflammation of the 
nose leads to nasal congestion and osteomeatal 
complex obstruction with reduced ventilation of 
the paranasal sinuses. Such conditions, especial-
ly in asthmatic children 22,23, facilitate the ascent 
of respiratory pathogens (Streptococcus pneu-
moniae, Haemophilus influenzae and Moraxella 
catharralis) that colonize the nasopharynx, may 
spread to the tympanic cavity and paranasal si-
nuses, and may subsequently lead to complica-
tions in the middle ear and paranasal sinuses that 
mainly manifest later in adulthood. 
Usually the treatment of these conditions re-
quires topical or systemic anti-inflammatory 
drugs or antibiotics. On the other hand, excessive 
use of antibiotics, especially in Western countries, 
has resulted in the selection of strains resistant to 
treatment. Resistance becomes even more im-
portant in light of the increasing difficulty in find-
ing new effective antibiotic compounds. Against 
this backdrop, alternative therapeutic approaches 
must be found that offer greater specificity and 
safety, avoid drug interactions, and leverage rath-
er than compromise native complementary modes 
of action against microbial invaders, in order to 
improve health while drastically reducing the 
risk of further developing resistance. In the pres-
ent study, we noted that follow-up at 12 months 
would approximate seasonal conditions at month 
zero, and thus suspect seasonal influence on 
symptoms to be minimal compared to therapeu-
tic effect. Therefore, we attribute the correlation 
of increased amelioration with longer exposure to 
therapy to the need for sufficient intervention to 
obtain a satisfactory colonization of the URT.
Conclusions
Treatment and prevention of otolaryngologic 
diseases in children are now a primary focus of 
pediatric medical care. The topical application of 
streptococcal probiotics is a relatively undeveloped 
field but is becoming an attractive approach for 
both prevention and therapy, especially for pediat-
ric age patients24. In this context, our data confirm 
the efficacy of Streptococcus salivarius 24SMB 
and Streptococcus oralis 89a as suitable bacterio-
therapeutic agents against URT infections.
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